Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Combined Treatment Clear all
Completed Phase 1Phase 2 Interventional Results available

Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma

NCT00715793
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Decitabine, Temozolomide, biopsy
Drug · Procedure
Lead sponsor
Hussein Tawbi
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Sep 28, 2026, 11:47 PM EDT
Active, not recruiting Phase 4 Interventional

Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)

NCT06854614
View directory record Official record
Conditions
Obesity
Interventions
Comprehensive weight loss, Enhanced lifestyle changes, Phentermine-Topiramate, Naltrexone-Bupropion Combination, Orlistat
Other · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 28, 2026, 11:47 PM EDT
Recruiting Phase 1 Interventional

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT05967416
View directory record Official record
Conditions
Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
Interventions
SIRPant-M, External-beam radiotherapy (XRT)
Biological · Radiation
Lead sponsor
SIRPant Immunotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Duarte, California • Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Sep 28, 2026, 11:47 PM EDT
Completed Phase 1 Interventional Results available

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

NCT05483933
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
Interventions
Pegylated Liposomal Doxorubicin + SL-172154, Mirvetuximab + SL-172154
Drug
Lead sponsor
Shattuck Labs, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Little Rock, Arkansas • Duarte, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 28, 2026, 11:47 PM EDT
Completed Not applicable Interventional

Endoscopic Gastric Mucosal Ablation as a Primary Obesity Therapy

NCT05486338
View directory record Official record
Conditions
Obesity, Adiposity
Interventions
Hybrid Argon Plasma Coagulation (HAPC)
Device
Lead sponsor
Erbe Elektromedizin GmbH
Industry
Eligibility
22 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Jacksonville, Florida • Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 28, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

NCT03815058
View directory record Official record
Conditions
Advanced Melanoma
Interventions
Autogene cevumeran, Pembrolizumab
Biological · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
17
States / cities
Duarte, California • La Jolla, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 28, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)

NCT00206726
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Alemtuzumab plus Fludarabine
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Berkeley, California • Burbank, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2016 · Synced Sep 28, 2026, 11:47 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

NCT05901285
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab
Interventions
VAX014, Nivolumab or pembrolizumab
Drug · Combination Product
Lead sponsor
Vaxiion Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Tucson, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 28, 2026, 11:47 PM EDT
Completed Phase 1 Interventional

Natural Vascular Scaffold (NVS) Therapy

NCT03148808
View directory record Official record
Conditions
Peripheral Arterial Disease, Peripheral Vascular Diseases, Catheterization, Peripheral
Interventions
NVS Therapy
Combination Product
Lead sponsor
Alucent Biomedical
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Columbus, Ohio • Wynnewood, Pennsylvania • Kingsport, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 28, 2026, 11:47 PM EDT
Not listed Phase 1 Interventional

Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

NCT00009776
View directory record Official record
Conditions
Lymphoma
Interventions
monoclonal antibody Lym-1, cyclosporine, paclitaxel, indium In 111 monoclonal antibody Lym-1, yttrium Y 90 monoclonal antibody Lym-1
Biological · Drug · Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 28, 2026, 11:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of a Personalized vs. Standard Approach to Weight Loss Recommendations

NCT04639076
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Behavioral Weight Loss Program, Personalized Behavioral Weight Loss Program
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
20 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 28, 2026, 11:47 PM EDT
Completed Phase 1 Interventional Results available

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

NCT00793793
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI201335, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 28, 2026, 11:47 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A

NCT01458106
View directory record Official record
Conditions
Hemophilia A
Interventions
BIIB031 (rFVIIIFc), FVIII (PK subgroup only)
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 28, 2026, 11:47 PM EDT
Completed Phase 1 Interventional

Carboxyamidotriazole and Ketoconazole in Treating Patients With Advanced Cancers

NCT00003249
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboxyamidotriazole, chemotherapy, ketoconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Sep 28, 2026, 11:47 PM EDT
Completed Phase 1 Interventional Results available

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

NCT03364348
View directory record Official record
Conditions
HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Utomilumab, Trastuzumab, Ado-Trastuzumab Emtansine
Drug
Lead sponsor
George W. Sledge Jr.
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Sep 28, 2026, 11:47 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy

NCT07804615
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder)
Interventions
VIM0423, VIM0423 Placebo
Drug
Lead sponsor
Vima Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
29
States / cities
Scottsdale, Arizona • Murrieta, California • Stamford, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 28, 2026, 11:47 PM EDT
Completed Phase 1 Interventional

17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor

NCT00087217
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
tanespimycin, paclitaxel, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Sep 28, 2026, 11:47 PM EDT
Terminated Phase 2 Interventional Results available

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

NCT01151215
View directory record Official record
Conditions
Neoplasms, Breast Neoplasms, Breast Cancer
Interventions
AZD8931, anastrozole, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Sep 28, 2026, 11:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment of Forehead/Glabellar Rhytide Complex With Combination Botulinum Toxin A and Hyaluronic Acid Versus Botulinum Toxin A Injection Alone

NCT01186835
View directory record Official record
Conditions
Forehead/Glabellar Rhytid Complexes
Interventions
Combination Botulinum Toxin A and Hyaluronic Acid, Botulinum Toxin A
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 28, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

NCT02855125
View directory record Official record
Conditions
Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
TAS-114, S-1
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Loma Linda, California • Gainesville, Florida • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 28, 2026, 11:47 PM EDT
Completed Phase 4 Interventional Results available

Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine

NCT04538040
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch
Drug
Lead sponsor
Quest Clinical Research
Other
Eligibility
45 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Sep 28, 2026, 11:47 PM EDT
Completed Phase 2 Interventional

Combination Pharmacotherapy for Smoking Cessation Among Methadone Patients

NCT00060814
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Combined intervention
Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 28, 2026, 11:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study Will Test the Theory That Training With the Facial-Flex Exercise Device Will Improve Snoring in Patients

NCT01554904
View directory record Official record
Conditions
Primary Snoring, Sleep Apnea
Interventions
Facial-Flex
Device
Lead sponsor
Facial Concepts, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Sep 28, 2026, 11:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

NCT01106352
View directory record Official record
Conditions
Bone Metastases, Castration-Resistant Prostate Cancer
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Docetaxel
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
San Francisco, California • Evanston, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 28, 2026, 11:47 PM EDT